Loading...
Market
Percentage reduction in glucocorticoid doses with Crenessity by end of 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Clinical trial results and medical journals
Story
FDA Approves Neurocrine Biosciences' Crenessity, First New Treatment for CAH in 70 Years
Dec 13, 2024, 08:13 PM
The U.S. Food and Drug Administration (FDA) has approved Neurocrine Biosciences' Crenessity (crinecerfont) for the treatment of adults and pediatric patients over 4 years of age with classic congenital adrenal hyperplasia (CAH). This approval marks the first new treatment option for CAH in 70 years, offering a paradigm-shifting approach by directly reducing excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction. The approval was supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAH. Crenessity is expected to be commercially available in approximately one week.
View original story
Similar markets
Less than 20% reduction • 25%
20% to 30% reduction • 25%
31% to 40% reduction • 25%
More than 40% reduction • 25%
Below 40% • 25%
40% - 50% • 25%
50% - 60% • 25%
Above 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
Decrease or no change • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Yes • 50%
No • 50%
Less than 50% • 33%
50% to 75% • 33%
More than 75% • 33%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 50% • 25%
50% to 74% • 25%
75% to 80% • 25%
More than 80% • 25%
Less than 20% • 25%
20% to 30% • 25%
31% to 40% • 25%
More than 40% • 25%
Less than 15% • 25%
15% to 20% • 25%
20% to 25% • 25%
More than 25% • 25%